Zacks Investment Research on MSN
Insulet broadens Omnipod 5 presence with commercial launch in Spain
Insulet Corporation PODD has commercially launched its Omnipod 5 Automated Insulin Delivery (AID) system and the Omnipod ...
Insulet (PODD) has drawn fresh attention after announcing the commercial launch of its Omnipod 5 Automated Insulin Delivery ...
Adults with type 2 diabetes achieved higher time in range with the next-generation Omnipod 6 automated insulin delivery ...
Insulet has begun shipping Omnipod 5 pods with the new algorithm to US retailers ahead of a broader software update.
Insulet Corporation PODD recently made its Omnipod 5 Automated Insulin Delivery (“AID”) System commercially available in Australia. Omnipod 5 is available with Dexcom G6 and G7 continuous glucose ...
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced the commercial launch of its ...
Insulin pump-maker Insulet has scored FDA 510(k) clearance for its Omnipod 5 Automated Insulin Delivery System for people ages 6 and up with Type 1 diabetes. The pump integrates with the Dexcom G6 ...
A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain ...
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...
The U.S. Food and Drug Administration (FDA) has designated Insulet Corp.’s PODD recall of certain Omnipod insulin delivery ...
Omnipod 5 Automated Insulin Delivery System now available in 20 countries worldwide New web-based data platform Omnipod Discover simplifies diabetes insights for users, caregivers, and healthcare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results